Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-Acetylcysteine for Post-COVID Respiratory Impairment
NCT05736887Phase 2Unknown
- Sponsor
- Policlinico Gemelli
- Start
- May 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in interstitial lung disease (ILD) comparing N-Acetylcysteine with Placebo (2 arms). Primary endpoint: Diffusing Capacity of the Lungs for Carbon Monoxide at 12 weeks. Status: unknown.
02
Drugs
acetylcysteine
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT05736887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05736887.